Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Stock-Based Compensation Expense

The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations:

	Three Months Ended March 31,
	2023		2022
(in thousands)	unaudited		unaudited
Research and development, net	$	674	$	546
Clinical operations, net		120		122
Sales and marketing		391		777
General and administrative		1,118		923
Total stock-based compensation expense	$	2,303	$	2,368